Event Abstract

Astrocytic CB1R enhances GLAST activity in a Ca2+ dependent manner

  • 1 Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Portugal
  • 2 Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal
  • 3 School of Biosciences, College of Biomedical and Life Sciences, Cardiff University, United Kingdom
  • 4 Instituto Superior de Engenharia de Lisboa, Portugal

Astrocytes perform many functions at the synapse level, including glutamate uptake, which is mainly mediated by specific glutamate transporters, GLT-1 and GLAST transporter (Perego et al., 2000) that are responsible for preventing excitotoxicity and for modulating synaptic function. Astrocytes can communicate with surrounding astrocytes and neurons by changes in the intracellular Ca2+ (Perea and Araque, 2005), being this achieved through the expression of several types of receptors in their membranes such as the cannabinoid type one receptor (CB1R) whose activation leads to Ca2+ mobilization from internal cellular stores (Navarrete and Araque, 2008). Thus, the aim of this work was to study the role of astrocytic CB1R activation-mediated Ca2+ signaling upon GLAST in rat primary astrocytic cultures. Primary cortical astrocytic cultures were prepared from Sprague Dawley pups (0-2 days old). Variations in [Ca2+]i were detected by Ca2+ imaging technique using fura 2-acetoxymethyl ester (Fura2AM, 5 M). The transport was initiated by addition of [3H]glutamate and the specific transport mediated by GLAST was accessed in presence of UCPH-101. Ca2+ signalling and [3H]-glutamate uptake experiments were performed with 18-23 DIC astrocytes. It was observed that astrocytic CB1R activation with ACEA, a CB1R specific agonist, led to Ca2+ transients, whose amplitude and frequency was dose-dependent for the two tested ACEA concentrations (0.5 and 1.0 µM, n = 3-7 independent cultures). The occurrence of these transients were impaired in the presence of a PLC antagonist (U73122, 3 µM) and a intracellular Ca2+ stores depletory (CPA, 10 µM). Low extracellular Ca2+ concentration decreased both frequency and amplitude of the transients. Regarding glutamate uptake, astrocytic CB1R activation increased significantly the maximum velocity of transport (Vmax) of GLAST transporter without significant changes in affinity (Km). This enhancement was lost in the presence of U73122 and a Ca2+ chelant (BAPTA, 20 µM), but not with a PKC antagonist (GF 10109203X, 1 µM). In conclusion, in astrocytes, CB1R activation triggers Ca2+ transients by PLC activation, in a dose-dependent manner enhancing GLAST activity probably by increasing the number of functional transporters at the astrocytic membrane.

Acknowledgements

This project was funded by Fundação para a Ciência e a Tecnologia (PTDC/BTM-SAL/32147/2017).

Keywords: Astrocytes, CB1R, Glutamate Uptake, Calcium, Cannabinoids

Conference: XVI Meeting of the Portuguese Society for Neuroscience (SPN2019), Lisboa, Portugal, 30 May - 1 Jun, 2019.

Presentation Type: Poster presentation

Topic: Glia / Neuroinflammation

Citation: Gonçalves-Ribeiro J, Morais TP, Savchak O, Meneses C, Sebastião AM and Vaz SH (2019). Astrocytic CB1R enhances GLAST activity in a Ca2+ dependent manner. Front. Cell. Neurosci. Conference Abstract: XVI Meeting of the Portuguese Society for Neuroscience (SPN2019). doi: 10.3389/conf.fncel.2019.01.00039

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 16 Apr 2019; Published Online: 26 Apr 2019.

* Correspondence: Dr. Sandra H Vaz, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, svaz@medicina.ulisboa.pt

© 2007 - 2019 Frontiers Media S.A. All Rights Reserved